Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Studies how centralized surgery affects outcomes for ovarian cancer patients

Follows adults with epithelial ovarian cancer treated from 2018 to 2023 in Emilia-Romagna.

Key facts

Who runs it
Azienda USL Reggio Emilia - IRCCS
Where
Carpi, Mirandola, Modena, Pavullo nel Frignano, Reggio Emilia, Sassuolo, and Vignola, ItalySee the 7 sites
Trial code
Registry title
Centralization and Oncologic Outcomes in Ovarian Cancer
Status
Recruiting
People taking part
200 people, planned
Started
27 Jun 2025
Expected to end
Jun 2031
Type of study
Observational, 3 groups
Treatments tested
  • No Intervention: Observational Cohort
Record updated
24 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with epithelial ovarian cancer who were treated between 2018 and 2023 and reviewed by the tumor board at AUSL-IRCCS Reggio Emilia.

Age
18 to 99 years
Sex
Women only
Disease stage
Epithelial ovarian cancer confirmed by tissue or cell tests (histological and/or cytological diagnosis)
Earlier treatment
Treated between January 1, 2018 and December 31, 2023

Main reasons for not taking part

  • No tissue or cell confirmation of epithelial ovarian cancer
  • Incomplete or missing data for key clinical indicators
  • Unable to give consent and cannot be contacted again
  • Unable to understand and give consent, for example severe cognitive impairment

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Female patients aged between 18 and 99 years
  • Histological and/or cytological diagnosis of epithelial ovarian cancer
  • Patients evaluated by the Multidisciplinary Tumor Board (MTB) of the AUSL-IRCCS of Reggio Emilia
  • Patients treated between January 1, 2018, and December 31, 2023
  • Availability of clinical records and outcome data
  • Signed informed consent where possible, in accordance with GDPR and Italian regulations

Who cannot take part

  • Patients without histological or cytological confirmation of epithelial ovarian cancer
  • Patients deemed unable to understand and provide consent (e.g., severe cognitive impairment)
  • Incomplete or missing data for key clinical indicators
  • Patients unable to provide informed consent and for whom recontact is not possible

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in Italy

  • Azienda Unità - Sanitaria locale di Modena - Ospedale Razzini CarpiCarpi, ItalyContact: Donatella Giardina, MDTaking people
  • Azienda Unità - Sanitaria locale di Modena - Ospedale di MirandolaMirandola, ItalyContact: Donatella Giardina, MDTaking people
  • Azienda Ospedaliero - Universitario di ModenaModena, ItalyContact: Cinzia Baldessari, MDTaking people
  • Azienda Unità - Sanitaria locale di Modena - Ospedale Pavullo nel FrignanoPavullo nel Frignano, ItalyContact: Eleonora Molinaro, MDNot yet recruiting
  • Azienda USL IRCCS di Reggio EmiliaReggio Emilia, ItalyContact: Vincenzo Dario Mandato, MD PhDTaking people
  • Azienda Unità - Sanitaria locale di Modena - Ospedale Civile SassuoloSassuolo, ItalyContact: Eleonora Molinaro, MDTaking people
  • Azienda Unità - Sanitaria locale di Modena - Ospedale di VignolaVignola, ItalyContact: Eleonora Molinaro, MDNot yet recruiting

About the trial

What the trial wants to find out

This is a multicenter, observational, retrospective and prospective study conducted within the REMO (Reggio Emilia - Modena) network in the Emilia-Romagna region (Italy), promoted by AUSL-IRCCS of Reggio Emilia.

Read full original descriptionShow less

The study aims to evaluate the impact of surgical centralization and treatment strategies adopted during the COVID-19 pandemic on oncologic outcomes in patients diagnosed with the epithelial ovarian cancer (EOC) from 2018 to 2023.

The retrospective component includes patients treated between 2018 and 2023, while the prospective component consists of clinical follow-up of those patients over the next five years.

The 3 groups in the trial

  • Pre-pandemic cohort (Group A)

    Patients with epithelial ovarian cancer treated between January 2018 and December 2019, before the implementation of centralization policies and before the onset of the COVID-19 pandemic. Standard care was provided based on local resources and clinical practice guidelines at the time.

    Treatment: No Intervention: Observational Cohort

  • Pandemic peak cohort(Group B)

    Patients treated between January 2020 and December 2021, during the most critical phase of the COVID-19 pandemic. Centralization of care and multidisciplinary decision-making were consistently applied.Treatment decisions were influenced by reduced hospital resources, increased use of neoadjuvant chemotherapy, and enhanced centralization of surgical procedures.

    Treatment: No Intervention: Observational Cohort

  • Post-peak pandemic cohort(Group C)

    Patients treated between January 2022 and December 2023, during the phase of pandemic control. Centralization of care and multidisciplinary decision-making were consistently applied. This group reflects the new post-pandemic organizational standards.

    Treatment: No Intervention: Observational Cohort

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Centralization and Oncologic Outcomes in Ovarian Cancer: A Multicenter Retrospective and Prospective Observational Study Within the REMO Network (COOC-REMO)
Plain-language title
Studies how centralized surgery affects outcomes for ovarian cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07075939, who can take part
Record updated
24 July 2026